What You Should Know About NAION Lawsuits Related to GLP-1 Use People taking glucagon-like peptide-1 (GLP-1) medications for diabetes or weight loss have experienced a significantly higher rate of the development of non-arteric ischemic optic neuropathy (NAION)
Dodson, Min Du Molecular Nutrition & Food Research.2017;[Epub] CrossRef Adipoz doku ve enerji metabolizmas zerine etkileri Meltem Mermer, Nilfer Acar TEK SD Salk Bilimleri Dergisi.2017;[Epub] CrossRef Physiological roles of macrophages Siamon Gordon, Luisa Martinez-Pomares Pflgers Archiv - European Journal of Physiology.2017
Clinical trials with GLP-1 receptor agonists consistently demonstrate significant weight loss, with higher doses (such as semaglutide 2.4 mg weekly) producing approximately 15% average weight loss in adults without diabetes in clinical trials (somewhat less in type 2 diabetes) when combined with lifestyle modification
Standard reduced glutathione in capsule form has bioavailability below 25% and requires higher doses (15002000mg) to achieve the same plasma concentrations
A p-value of less than 0.05 was considered statistically significant
The study did show a handful of food categories showing increases in spending
